tbuckley/cabot-search huggingface dataset:
SAT0129 Vitamin D Status and Its Association with Disease Activity, Severity and Physical Disability in Rheumatoid Arthritis Patients
Authors: O. Akkar, L. Ichchou
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Vitamin D has immunomodulatory effects in a wide range of human autoimmune diseases; including Rheumatoid Arthritis (RA). Vitamin D deficiency is common in RA. <h3>Objectives</h3> The objective of this study was to evaluate vitamin D status in RA patients and assess the relationship between vitamin D levels, disease activity, severity and physical disability. <h3>Methods</h3> We included in this cross-sectional study patients with RA according to ACR/EULAR classification criteria, followed up at the Department of Rheumatology. Demographic characteristics and disease specific variables were collected. Disease activity was assessed by the Disease Activity Score (DAS 28). Functional disability was evaluated by the Health Assessment Questionnaire (HAQ). Joint destruction was assessed by the van der Heijde-modified Sharp Score. Serum concentrations of 25(OH) Vitamin D were measured. According to the GRIO recommendations, 25(OH)D insufficiency was defined as 25(OH)D ranging from 10 to 30 ng/mL, and deficiency as 25(OH)D &lt;10 ng/mL. Data analysis was carried out using the SPSS 20 Software. p&lt;0.05 was considered statistically significant. <h3>Results</h3> Seventy-tree patients with a mean±SD age of 52.04 ± 12.26 years were enrolled. Sixty-nine percent were females. Mean±SD duration of symptoms was 11.61 ± 8.43 years. The prevalence of 25(OH)D insufficiency and deficiency was 69.9% and 17.8% successively. The univariate analysis showed a significant correlation between 25(OH)D serum concentration, number of swollen joints (p=0.024) and disease activity (p=0.012). In multivariate analysis adjusted for age, Sharp score, and C-Reactive Protein, there was a significant correlation between 25(OH)D serum concentration and disease activity (p=0.048). <h3>Conclusions</h3> Vitamin D deficiency is highly prevalent and is associated with higher disease activity in our RA patients. Therefore, Vitamin D measurement and possibly vitamin D supplementation should be considered in the management of RA patients. <h3>Disclosure of Interest</h3> None declared
P0783 : Viral kinetics during interferon-free sofosbuvir containing treatment regimens in a real-life cohort of chronic hepatitis C patients with advanced liver disease
Authors: K. Kozbial, C. Freissmuth, R. Strassl, R. Al-Zoairy, A. Maieron, R. Stauber, M. Gschwantler, M. Strasser, H. Laferl, T. Bamberger, S. Moser, M. Eder, S. Beinhardt, A.F. Staettermayer, M. Mandorfer, A. Ferlitsch, H. Zoller, P. Knoflach, K. Staufer, M. Peck-Radosavljevic, P. Munda, W. Vogel, P. Ferenci, H. Hofer
Journal: Journal of Hepatology (2015)
Beast of Pulmonary Arterial Hypertension Burden
Authors: Stephen C. Mathai, Vallerie V. McLaughlin
Journal: JAMA Cardiology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
BMA relinquishes ability to take strike action over junior contract
Authors: Abi Rimmer
Journal: BMJ (2016)

The BMA has given up its ability to take industrial action over changes to the junior doctor contract in England.

In an email to members on Thursday 10 November, Peter Campbell, interim chair of the BMA junior doctors committee, said that the committee had decided to end its current mandate for industrial action. The decision means that a fresh ballot would be needed before any future industrial action.

The phased implementation of the new junior doctor contract began in October, with trainees in obstetrics being the first to …
Erythropoietin Use In Patients with AML or Undergoing Allogeneic HSCT Significantly Improves Quality of Life and Reduces Red Blood Cells and Platelets Transfusions without Any Survival Effect.
Authors: Mauricette Michallet, Karine Goldet, Stephane Morisset, Mohamad Sobh, Youcef Chelghoum, Xavier Thomas, Helene Labussiere, Sophie Ducastelle, Fiorenza Barraco, Jean Vial, Catherine Renzullo, Carole Paillet, Christine Pivot, Perrine Badol-Van Straaten, Angelique Denis, Anne Termoz, Franck E Nicolini, Isabelle Jaisson-Hot
Journal: Blood (2010)
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma
Authors: Kent W. Mouw, James M. Cleary, Brendan Reardon, Jonathan Pike, Lior Z. Braunstein, Jaegil Kim, Ali Amin-Mansour, Diana Miao, Alexis Damish, Joanna Chin, Patrick A. Ott, Charles S. Fuchs, Neil E. Martin, Gad Getz, Scott Carter, Harvey J. Mamon, Jason L. Hornick, Eliezer M. Van Allen, Alan D. D'Andrea
Journal: Clinical Cancer Research (2016)

Purpose: Squamous cell carcinoma of the anal canal (ASCC) accounts for 2% to 4% of gastrointestinal malignancies in the United States and is increasing in incidence; however, genomic features of ASCC are incompletely characterized. Primary treatment of ASCC involves concurrent chemotherapy and radiation (CRT), but the mutational landscape of resistance to CRT is unknown. Here, we aim to compare mutational features of ASCC in the pre- and post-CRT setting.Experimental Design: We perform whole-exome sequencing of primary (n = 31) and recurrent (n = 30) ASCCs and correlate findings with clinical data. We compare genomic features of matched pre- and post-CRT tumors to identify genomic features of CRT response. Finally, we investigate the mutational underpinnings of an extraordinary ASCC response to immunotherapy.Results: We find that both primary and recurrent ASCC tumors harbor mutations in genes, such as PIK3CA and FBXW7, that are also mutated in other HPV-associated cancers. Overall mutational burden was not significantly different in pre- versus post-CRT tumors, and several examples of shared clonal driver mutations were identified. In two cases, clonally related pre- and post-CRT tumors harbored distinct oncogenic driver mutations in the same cancer gene (KRAS or FBXW7). A patient with recurrent disease achieved an exceptional response to anti-programmed death (PD-1) therapy, and genomic dissection revealed high mutational burden and predicted neoantigen load.Conclusions: We perform comprehensive mutational analysis of ASCC and characterize mutational features associated with CRT. Although many primary and recurrent tumors share driver events, we identify several unique examples of clonal evolution in response to treatment. Clin Cancer Res; 23(12); 3214-22. ©2016 AACR.
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)
Authors: Sven de Vos, Marshall T. Schreeder, Ian W. Flinn, Steven E. Coutre, John P. Leonard, Nina D. Wagner-Johnston, Nathan H. Fowler, Ralph V. Boccia, Jaqueline C. Barrientos, Thomas Boyd, Jeff Sharman, Leanne Holes, Brian Lannutti, Dave M. Johnson, Thomas M. Jahn, Langdon L Miller
Journal: Blood (2011)
The Percentage of Cytotoxic T-Cells in Mantle Cell Lymphoma (MCL) Biopsies Predicts Response to Rituximab.
Authors: Stephen Opat, Pedro Farinha, Merrill Boyle, Nathalie Johnson, Hilary OLeary, James R. Cook, Raymond R. Tubbs, Lin Wang, Ryan Woods, Joseph M. Connors, Randy D. Gascoyne
Journal: Blood (2009)
Novel Germ Line Mutations in the KRAS2 Gene Cause Noonan Syndrome and Deregulate Hematopoietic Cell Growth.
Authors: Suzanne Schubbert, Martin Zenker, Sara L. Rowe, Silke Böll, Cornelia Klein, Ineke van der Burgt, Luciana Musante, Hoa Nguyen, Brian West, Gideon Bollag, Charlotte M. Niemeyer, Kevin M. Shannon, Christian P. Kratz
Journal: Blood (2005)
Relationship between Conditioning Intensity and Comorbidity in Patients (Pts) with Acute Myeloid Leukemia (AML) or Myelodysplasia (MDS) Receiving Allogeneic Hematopoietic Cell Transplantation (HCT).
Authors: Mohamed Sorror, Barry Storer, Brenda M. Sandmaier, Michael Maris, Frederic Baron, David Maloney, Bart Scott, H. Joachim Deeg, Rainert Storb
Journal: Blood (2005)
AB0512 Use of Nominal Group Technique To Facilitate Item Reduction for Sle Classification Criteria Development: Table 1.
Authors: S. Johnson, D. Khanna, R. Cervera, N. Costedoat-Chalumeau, D.D. Gladman, B.H. Hahn, F. Hiepe, J. Sanchez-Guerrero, E. Massarotti, D. Boumpas, K. Costenbader, D. Daikh, D. Jayne, T. Dorner, D. Kamen, M. Mosca, R. Ramsey-Goldman, J.S. Smolen, D. Wofsy, M. Aringer
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Criteria for the classification of SLE are being developed with the support of EULAR and ACR. Two independent exercises (expert-based Delphi exercise and data-driven cohort evaluation of early SLE and controls) were undertaken to generate candidate criteria, and then reduce them to a smaller set. <h3>Objectives</h3> To select a set of items that maximizes the likelihood of SLE in a person with an uncertain diagnosis. <h3>Methods</h3> A panel of seven international SLE experts (reflecting practice in Spain, France, Germany, United States, Canada and Mexico) was asked to rank 41 candidate criteria nominated in the Delphi and cohort studies. The rankings were presented at a face-to-face meeting of the expert panel and steering committee. A consensus meeting using nominal group technique (NGT) was conducted to reduce the list of criteria for consideration. Redundant or poorly performing criteria were removed. <h3>Results</h3> This expert panel NGT exercise reduced the candidate criteria for SLE classification from 41 to 21. The panel distinguished potential "entry criteria", which would be required for classification, from other potential "additive criteria", summarized in Table 1. Entry criteria were ANA by hep 2 immunofluorescence ≥1:80, and low C3 and/or low C4. Additional work is needed to refine definitions*, to evaluate their independence and relationships within domains, and to ascertain item weights. <h3>Conclusions</h3> This expert panel NGT exercise resulted in 21 candidate SLE classification criteria. Refinement of definitions, ability to cluster criteria into domains and weighting of criteria will be ascertained in the next phase. <h3>Acknowledgement</h3> This work was supported by EULAR and ACR <h3>Disclosure of Interest</h3> None declared
FRI0490 Infertility and Pregnancy in Rheumatic Diseases: The Utility of A Multidisciplinary Protocol for The Management of These Patients
Authors: I.C. Chalmeta, J. Ivorra, B. Marcos, C. Diaz, E. Beltran, R. Negueroles, J.L. Valero, C. Feced, F. Ortiz, L. Gonazlez, I. Martinez, E. Labrador, K. Arevalo, E. Grau, C. Alcañiz, J. Fragio, J. Roman
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Pregnancy in rheumatic diseases is a process that requires careful handling, beginning with proper planning. Infertility and chronic use of teratogenic drugs are some common situations in these patients, giving them a high-risk obstetrics. <h3>Objectives</h3> To established a protocol for planning and monitoring pregnancies in patients with rheumatic diseases <h3>Methods</h3> Retrospective review of a follow-up protocol for patients with rheumatic diseases and pregnancy wishes. This protocol includes: preconception consultation to asses fertility of the couple, as well as pregnancy couselling and establishment of a appropriate pharmacological treatment; after pregnancy period start, monthly consultations by a multidisciplinary team; and finally, a postpartum consultation after delivery <h3>Results</h3> A total of 51 patient with different rheumatic diseases were included: Sistemic Lupus Erythematosus (8 patients), Sjogren9S Syndrom (10 patients), Rheumatoid arthritis (13 patients), Psoriatic arthritis (5 patients), Behcet9s disease (3 patients), Spondiloarthritis (2 patients), Familial Mediterranean Fever (2 patients), Conective mixed Tissues Disease (1 patient), Primary Antiphospholipi Syndrom (2 patient) an Hyper IgD Syndrome (1 patient). The results were: Infertility was detected in 8 couples and assisted reproductive techniques was requieres in 7 (6 IVF and 1 insemination). Safe Pharmacological treatments were used: sulfasalazine (4), hydroxychloroquine (13), azathioprine (2). Biological DMARDs in 3 patients (1 infliximab and Certlizumab in 2). Other treatments were: steroids (12) and intravenosus immunoglobulins for fetal heart block (2). All patients with thrombophilia have been treated with LMWH alone or plus aspirin. The course of pregnancy was:delivery at term (28), delivery pre-term (3)**, miscariages (3)*, pregnancy on course (7), neonatal death (1) and 8 patients are plannig the pregnancy. The abortions have occurred in 2 patients with lupus erythematosus and in 1 patient with rheumatoid arthritis. Postpartum care of newborns with mothers with positivity anti-Ro has objectified a neonatal transfer of Acs in 100% of cases;only 8 of them developed neonatal SLE. <h3>Conclusions</h3> A satisfactory evolution of pregnancy was observed in 87% of our patients, a fact that supports our impression that this process should be approached in a multidisciplinary team. Infertility is a situation that should be considered and treated at an early stage in this patients, preferably before preconceptional period. <h3>Disclosure of Interest</h3> None declared
AB0530 25-Hydroxyvitamin D3 Deficiency: Prevalance and Its Impact on Disease Activity in Small-Medium Vessel Vasculitis
Authors: F.N. Korkmaz, G. Ozen, A.U. Unal, M. Can, S. Tuglular, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Growing evidence suggests that vitamin D has important immunomodulatory effects and plays key roles in endothelial dysfunction, atherosclerosis and pathogenesis/progression of some of the inflammatory rheumatic diseases such as rheumatoid arthritis and systemic lupus erythematosus. Although recent data indicated that vitamin D deficiency is quite prevalant and affects endothelial dysfunction in Behcet9s Disease and Takayasu9s arteritis, vitamin D levels in small/ medium vessel vasculitis and its effects on disease course have not been evaluated. <h3>Objectives</h3> To determine the prevalance of 25-hidroxyvitamin D3 [25(OH)D3] deficiency and to investigate its effects on disease activity in patients with small and/or medium vessel vasculitis. <h3>Methods</h3> In this cross-sectional study, 25(OH)D3 levels were measured in adult patients with systemic small-medium vessel vasculitis including ANCA-associated vasculitis (AAV), cryoglobulinemic vasculitis (CryV), IgA vasculitis (IgAV) and polyarteritis nodosa (PAN), and sex-matched healthy subjects (HS). All patients9 baseline demographics, disease characteristics, acute phase reactants, medications and disease extents (DEI), disease activities (BVAS) and damage scores (VDI) were determined. 25(OH)D3 level &lt;30ng/ml and &lt;20ng/ml were regarded as insufficiency and deficiency, respectively. <h3>Results</h3> Forty five patients (29% new diagnosis) with systemic vasculitis and 63 HS were included (<i>Table 1</i>). The mean 25(OH)D3 level was 21.8±14.3 ng/mL in patients with vasculitis and 56.7±23.9 ng/mL in HS (p&lt;0.001). Vitamin D insufficiency and deficiency were significantly higher in patients with vasculitis compared to HS (<i>Table 1</i>). Thirty eight patients (84.4%) were active (BVAS≥1) at the time of recruitment. 25(OH)D3 levels were not different in active (21.6±14.8) and inactive (23.1±12.1) patients (p=0.79). Of the 24 vitamin D deficient patients 23 (95.8%) had renal involvement. Vitamin D deficient patients had slightly higher BVAS (6.5±6.7 vs 3.7±3.7), VDI (3.8±1.4 vs 3.2±1.3) and DEI (3.0±2.8 vs 1.8±2.4) scores at recruitment but the differences were not statistically significant (p&gt;0.05). Likewise there was no difference in acute phase reactants according to vitamin D status. <h3>Conclusions</h3> Vitamin D insufficiency and deficiency are quite common in patients with small/medium vessel systemic vasculitis. In this preliminary study we could not demonstrate any association with vitamin D deficiency and disease activity in patients with vasculitis. However, prospective followup of a larger sample would better clarify the role of vitamin D on disease activity. Considering also the use of high dose glucocorticoid treatment, these patients should be adequately evalauted and treated for vitamin D deficiency. <h3>Disclosure of Interest</h3> None declared
Outcomes and Temporal Trends of Inpatient Percutaneous Coronary Intervention at Centers With and Without On-site Cardiac Surgery in the United States
Authors: Kashish Goel, Tanush Gupta, Dhaval Kolte, Sahil Khera, Gregg C. Fonarow, Deepak L. Bhatt, Mandeep Singh, Charanjit S. Rihal
Journal: JAMA Cardiology (2016)

There are concerns whether percutaneous coronary intervention (PCI) at centers without on-site cardiac surgery is safe outside of a tightly regulated research environment. To analyze the outcomes and temporal trends of inpatient PCI at centers without on-site cardiac surgery in an unselected and nationally representative population of the United States. A national inpatient sample (N = 6 912 232) was used to identify patients who underwent inpatient PCI in the United States from January 1, 2003, to December 31, 2012. Hospitals that performed 1 or more coronary artery bypass graft surgeries in a given calendar year were classified as centers with on-site cardiac surgery, and weighted sampling of all inpatient hospitalizations was performed. Data analysis was performed from February to May 2016. Inpatient PCI. In-hospital mortality. Of the 6 912 232 inpatient PCIs performed, 2 336 334 patients (33.8%) were women and 4 575 898 (66.2%) were men; their mean (SD) age was 64.5 (12.3) years. Of these PCIs, 396 741 (5.7%) were conducted at centers without on-site cardiac surgery. The rate of in-hospital mortality was significantly lower at centers with on-site cardiac surgery compared with centers without on-site cardiac surgery (1.4% vs 1.9%; unadjusted odds ratio [OR], 0.74; 95% CI, 0.72-0.75). After adjustment, there was no significant difference in in-hospital mortality between centers with and without on-site cardiac surgery (OR, 1.01; 95% CI, 0.98-1.03; P = .62) for acute coronary syndromes and elective procedures requiring inpatient hospitalization. In addition, there were no significant differences in the risk-adjusted, in-hospital mortality between the 2 groups in prespecified subgroups after adjusting for multiple comparisons, including ST-elevation myocardial infarction (OR, 0.99; 95% CI, 0.96-1.03; P = .65), non-ST-elevation acute coronary syndrome (OR, 0.99; 95% CI, 0.93-1.05; P = .66), and elective PCI (OR, 0.93; 95% CI, 0.84-1.03; P = .17). There was a significant increase in the proportion of PCIs at centers without on-site cardiac surgery within the study period (from 1.8% to 12.7%; P < .001 for trend by Cochrane-Armitage test) reflected across all the indications. There was a 7-fold increase in the proportion of PCIs at centers without on-site cardiac surgery from 2003 to 2012 in the United States, with the adjusted in-hospital mortality after inpatient PCI being similar at centers with and without on-site cardiac surgery. These data provide evidence that PCI at centers without on-site cardiac surgery may be safe in the modern era.
Pre-Operative Bone Marrow-Derived Cell Mobilization by G-CSF Enhances Osseointegration of Bone Substitute In Patients Undergoing Surgery with High Tibial Valgus Osteotomy
Authors: Antongiulio Marmotti, Castoldi Filippo, Rossi Roberto, Alessia Tron, Francesco Giacalone, Stefano Marenco, Cristina Realmuto, Alessandra Risso, Marco Ruella, Alda Borrè, Paolo Rossi, Corrado Tarella
Journal: Blood (2010)
AB0910 Investigation of The Arterial Stiffness and Related Factors in Patients with Acrocyanosis
Authors: M. Cakar, M. Cinar, S. Yilmaz
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Acrocyanosis is a disorder of the peripheral circulation and often arises due to cold, and describes the situation with diffuse blue-purplish discoloration of the hands and feet. Although its etiology is unknown, infections, malignancies, hematological disorders, neurological, psychiatric, autoimmune and metabolic status have all been suggested to contribute. It is more frequent in women and usually starts during the third decade. Unless there is another underlying disease, there is no data regarding whether these patients have increased risk of mortality and morbidity or not, compared to a healthy people. Arterial stiffness measurements have long-term high predictive value, accessibility, cost-effectiveness and repeatability for representing cardiovascular risk. <h3>Objectives</h3> To investigate long-term cardiovascular risk, determine factors that may play a role in the etiology and measure arterial stiffness in patients with acrocyanosis. <h3>Methods</h3> The study included 23 consecutive patients who were diagnosed as acrocyanosis and agreed to participate in the study (F/M: 1/22) and 17 healthy controls (F/M: 1/16) were included. Tensiomed Arteriograph device used for measuring arterial stiffness of the cases. T he demographic and clinical features, blood counts and routine laboratory tests were recorded and their relationships with arterial stiffness measurements were investigated. Correlation and regression analysis were used for the evaluation of the data. <h3>Results</h3> The mean age of the patient and control groups were similar (22.83±4.7 and 25.0±0.5 years, respectively, p=0.066). The average body mass indexes of the patient and control groups were also similar (21.6±2.6 and 22.7±1.3 kg/m 2). The average pulse wave velocity measurements were lower in acrocyanosis patients compared to controls, but the difference did not reach statistical significance (6.87 ±1.11 and 7.15±1.37 m/s, p=0.508). Pulse wave velocity measurements were associated with erythrocyte sedimentation rate (r =0.551, p=0.012). Ankle-brachial index (ABI) was associated with serum glucose levels (r =0.896, p&lt;0.001). Serum calcium levels were associated with aortic and brachial augmentation indexes (r =0.477 and 0.474; p=0.045 and 0.047, respectively). Patient and control groups had similar aortic and brachial augmentation indexes, and there was no significant difference between the groups in terms of central aortic pressures. <h3>Conclusions</h3> According to our study, arterial stiffness indexes representing cardiovascular risk were similar in patients with acrocyanosis compared to healthy population of the same age. However, the lower average pulse wave velocity measurements in acrocyanosis, need to be further investigated in a larger group. <h3>Disclosure of Interest</h3> None declared
The Role of Transcriptional Coactivator TRAP220/MED1 in Nuclear Receptor-Mediated Myelomonocytic Differentiation.
Authors: Mitsuhiro Ito, Norinaga Urahama, Akiko Sada, Kimikazu Yakushijin, Katsuya Yamamoto, Atsuo Okamura, Kentaro Minagawa, Akio Hato, Kazuo Chihara, Robert G. Roeder, Toshimitsu Matsui
Journal: Blood (2005)